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Abstract
Background: Understanding the role of different classes of T cells during HIV infection is critical to determining which
responses correlate with protective immunity. To date, it is unclear whether alterations in regulatory T cell (Treg) function
are contributory to progression of HIV infection.
Methodology: FOXP3 expression was measured by both qRT-PCR and by flow cytometry in HIV-infected individuals and
uninfected controls together with expression of CD25, GITR and CTLA-4. Cultured peripheral blood mononuclear cells were
stimulated with anti-CD3 and cell proliferation was assessed by CFSE dilution.
Principal Findings: HIV infected individuals had significantly higher frequencies of CD4
+FOXP3
+ T cells (median of 8.11%;
range 1.33%–26.27%) than healthy controls (median 3.72%; range 1.3–7.5%; P=0.002), despite having lower absolute
counts of CD4
+FOXP3
+ T cells. There was a significant positive correlation between the frequency of CD4
+FOXP3
+ T cells and
viral load (rho=0.593 P=0.003) and a significant negative correlation with CD4 count (rho=20.423 P=0.044). 48% of our
patients had CD4 counts below 200 cells/ml and these patients showed a marked elevation of FOXP3 percentage (median
10% range 4.07%–26.27%). Assessing the mechanism of increased FOXP3 frequency, we found that the high FOXP3 levels
noted in HIV infected individuals dropped rapidly in unstimulated culture conditions but could be restimulated by T cell
receptor stimulation. This suggests that the high FOXP3 expression in HIV infected patients is likely due to FOXP3
upregulation by individual CD4
+ T cells following antigenic or other stimulation.
Conclusions/Significance: FOXP3 expression in the CD4
+ T cell population is a marker of severity of HIV infection and a
potential prognostic marker of disease progression.
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Introduction
Many aspects of HIV pathogenesis are still poorly understood.
Despite the CD4 T cell depletion and resulting immunosuppres-
sion which are hallmarks of the disease, HIV infected individuals
display increased levels of immune activation as evidenced by
elevated expression of markers of cell activation such as HLA-DR,
CD38 and CD69 [1,2]. The contributory role of preservation or
destruction of regulatory T cells (Tregs), either in number or
function, has not been established.
Naturally occurring Tregs are a subset of CD4
+ T cells
expressing the forkhead-winged-helix transcription factor, Fork-
head box 3 or FOXP3 [3]. They are responsible for immunoreg-
ulation predominantly through cell-cell contact mediated suppres-
sion. It is plausible that preferential destruction or inactivation of
Tregs by HIV could lead to excessive immune activation [4,5].
Treg-mediated suppression of HIV specific responses in vitro has
been shown to be more effective with cells isolated from relatively
healthy HIV infected patients compared with later stage AIDS
patients, suggesting that Tregs (total or HIV-specific) were
depleted or dysfunctional later in HIV disease [6].
On the other hand, preferential preservation of Tregs over
other subsets of T cells could lead to suppression of immune
responses to viral infections, leading to a high viral load [7,8].
Various authors have described increased Tregs as a proportion of
CD4
+ T cells in HIV positive patients, particularly in those with
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+ T cell counts (CD4 counts) [9,10,11]. In peripheral
blood, Treg levels have been reported to remain elevated years
after successful highly active antiretroviral therapy [9,12,13].
Certain authors [14] have suggested that with progression from
HIV to AIDS the number of circulating CD4
+CD25hi Treg as a
proportion of CD4 T cells increases but their function (which was
measured by FOXP3 mRNA expression) decreases.
Generation of T cells expressing FOXP3 or with suppressor
activity has been reported to occur through incomplete activation
of CD4
+ T cells by immature, plasmacytoid or alternatively-
activated dendritic cells [15,16,17,18,19,20,21] in HIV-infected
individuals as well as in response to Vitamin D [22], all trans
retinoic acid [23,24,25,26] or indoleamine deoxygenase (IDO)
modulation in antigen presenting cells [20,27,28,29,30,31,32].
One or more of these mechanisms may by responsible for
alteration of FOXP3 expression in HIV infected individuals. The
end result may be a disproportionate increase in cells with a
suppressive or tolerant rather than a proinflammatory phenotype,
resulting in an inability of the host to combat pathogens.
There are a number of reasons why different studies may have
had contrasting findings. Principally, there is still no validated
marker with which to identify human Tregs. The best available to
date is forkhead box transcription factor P3, written ‘‘Foxp3’’ in
animals and ‘‘FOXP3’’ in humans. FOXP3 is a key control
element in the development and function of CD4
+ T cells with
suppressor function [33,34,35,36].
Use of other markers to identify Tregs have varied from study to
study and include CD25, Cytotoxic T lymphocyte associated
protein 4 (CTLA-4 or CD152), glucocorticoid-induced tumour
necrosis factor receptor (GITR), CD27, OX40 ([37], CD44 [38],
CD62L [39,40], CD39 [41] and decreased expression of CD127
[42,43,44]. Tregs are generally thought to be of memory
phenotype expressing CD45RO [8,45,46], although there have
been reports of naı ¨ve CD45RA Tregs [47,48,49]. None of these
markers are exclusive to the Treg population and many are also
expressed by activated CD4
+ T cells.
While Tregs are easily defined in mice by concurrent expression
of FOXP3 and high levels of CD25, in humans CD25 cannot be
clearly delineated into low and hi expressing subsets due to a
continuum of expression. In addition, CD25 expression does not
always correlate with FOXP3 expression in humans, particularly
in HIV infected individuals [31]. FOXP3 expression can be
triggered in FOXP3
2 CD4
+ T cells during activation or division
which may correlate with, perhaps transient, suppressive potential
[50,51,52,53,54,55]. There is also however conflicting evidence
suggesting that FOXP3 expression in humans may not be confined
to cells with regulatory function [44,56,57,58,59].
We analysed FOXP3 expression, as well as other Treg markers,
in South African patients with and without HIV infection. We
found a significantly elevated percentage of FOXP3 expressing
CD4
+ T cells in HIV infected patients, particularly in those with
lower CD4 counts. We explored the mechanism of FOXP3
upregulation by assessing the ability of cultured cells from HIV
positive and negative patients to maintain FOXP3 expression in
unstimulated conditions and following T cell receptor stimulation.
While many previous studies have isolated CD4
+CD25
hi cells and
mixed them with responder cells in a predetermined ratio such as
1:1 or 1:10, we avoided this approach as it does not reflect the
situation in vivo at a physiological ratio of Tregs to responder cells.
Additionally the isolation of Tregs by CD25hi sorting potentially
leaves FOXP3-expressing Tregs behind in the responder popula-
tion. We sought to investigate FOXP3 expression after T cell
receptor stimulation while maintaining a physiological ratio of
Tregs to responder cells. FOXP3 expression dropped rapidly in
unstimulated cell culture but was restored by T cell receptor
stimulation. This suggests that the high FOXP3 expression in HIV
infected patients is likely due to FOXP3 upregulation by individual
CD4
+ T cells following antigenic or other stimulation.
Materials and Methods
Clinical Samples
In this cross-sectional study, twenty-seven HIV infected patients
were recruited from the antiretroviral clinics of the Charlotte
Maxeke Johannesburg Academic hospital and health care centres
in Alexandra township, Johannesburg. Ten of the patients had
active Tuberculosis as diagnosed on the basis of symptoms and
sputum microscopy. As the HIV-infected patients with and
without active Tuberculosis did not differ from each other with
regards to CD4 count or FOXP3 expression (Figure 1A), they
were grouped together for further analysis. Patients had access to
the national antiretroviral programme but had not yet commenced
antiretroviral therapy or received more than four days of TB
treatment at study enrolment.
Twenty-two healthy controls were recruited from amongst
health-care workers of the institutions named above as well as
blood donors from the South African National Blood Transfusion
Service. Controls and HIV infected subjects were similar with
respect to gender and age. All subjects gave written informed
consent for the study and ethics approval was granted by the
Universityofthe WitwatersrandHumanMedicalEthicsCommittee
(R14/49). The day of sample collection was regarded as Day 0.
HIV tests and haematological parameters
The HIV status of participants was confirmed using HIV rapid
testing (Determine HIV-1/2, Abbott Laboratories, Abbot Park, Il
60064,USA). CD4 counting was performed using the PanLeuco-
gating method [60]. Viral loads were performed using the COBAS
Ampliprep/COBAS Taqman HIV-1 Test (Roche Diagnostics
Division, Basel, Switzerland).
Isolation of Peripheral Blood Mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
within 3–5 hours of sample collection using Ficoll Hypaque in
LeucoSep tubes. Cells were washed twice in Hanks Buffered Salt
Solution with 0.1% gentamycin and counted using a capillary
cytometer (Guava technologies, Hayward, CA). Cells (2610
6
cells/ml) were then rested overnight at 37uC in a 5% CO2
atmosphere in RPMI 1640 medium with GlutaMAX and 25mM
HEPES (Gibco, Scotland) supplemented with 20% fetal bovine
serum (Gemini Bio-Products, USA) and 0.1% gentamycin (R20).
mRNA extraction and qRT-PCR
mRNA was extracted from one million PBMCs per sample
using QIAamp RNA mini kit (QIAGEN, Germany). The mRNA
was immediately converted to cDNA using the Applied Biosystems
High-Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA) and the GeneAmp PCR System 9700 (Applied
Biosystems, Foster City, CA). cDNA was frozen at 220uC until
needed. Multiplexed real-time reverse transcriptase PCR was then
performed using TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA.) on the 7500 Real Time PCR System
(Applied Biosystems, Foster City, CA). FOXP3 expression was
assessed using a fluorescently labelled probe (TaqMan Gene
expression assays, probe Hs00203958_m1, Applied Biosystems,
Foster City, CA) relative to expression of gapdh (Pre-Developed
TaqMan Assay Reagents Control Kit, Applied Biosystems Foster
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of a blank control tube.
Cell stimulations
PBMC were rested overnight in R20 medium at 2610
6 cells/
ml with analysis of unstimulated samples on day 1. For
assessment of cell proliferation, an equal volume of 10mM CFSE
(Molecular Probes, Netherlands) was added to the unstimulated
PBMC suspension. Samples were vortexed and incubated at
room temperature in the dark for 7 minutes. To quench the
CFSE reaction, a double volume of ice cold FBS was added.
Samples were again vortexed and incubated at room temperature
in the dark for 1 minute. PBMC were washed twice with warm
RPMI 1640 medium with GlutaMAX and 25mM HEPES
(Gibco, Scotland) supplemented with 10% human serum AB
(Gemini Bio-Products, USA) and 0.1% gentamycin (R10) to
remove excess CFSE. 2610
6 CFSE stained cells were seeded in a
24-well culture plate (Nunc, Denmark) in R10 medium to a final
volume of 2ml. Stimulated samples were treated with 0.1 ug/ml
stimulatory anti-CD3 mAb (12F6). Unstimulated samples were
used as negative controls. Plates were incubated at 37uC, 5%
CO2 for 4 days.
Intracellular cytokine staining
Harvested PBMC (boththoserested overnight and thosecultured
for 4 days) were stained for intracellular FOXP3 and CTLA-4
expression and surface expression of CD25, GITR, CD3 and CD4
using the FOXP3 staining set (eBiosciences, UK) according to
manufacturer’s instructions. Mean FOXP3% is reported from
triplicate measurements. Preliminary experiments with propidium
iodide showed efficacy of cell permeabilisation to be above 98%.
Antibody-fluorochrome conjugates used included CD3 APC,
CD3 PerCP, CD4 FITC, CD4 PerCP, CD8 FITC,CD25 APC
(BD Biosciences, San Jose, CA), GITR APC, CTLA-4 FITC
(R&D Systems, Minneapolis, USA) and FOXP3 PE (clone
PCH101, eBiosciences, UK).
Flow cytometry
Flow cytometry was performed using FACSCalibur (BD Biosci-
ences) and LSRII (BD Biosciences) flow cytometers with acquisition
enabled by CellQuest Pro or FACSDiva software (BD Biosciences)
respectively. Colour compensation was achieved using an appropriate
single fluorochrome-labelled sample. Data was analysed using FlowJo
6.4.2 (TreeStar, USA). For CD25 quantitation, expression of CD25
on CD4
2 Tc e l l sw a su s e da sar e p r o d u c i b l er e f e r e n c ep o i n t .
Figure 1. FOXP3 expression at baseline in HIV infected patients. Panel A: Subgroup analysis of the HIV and HIV/TB coinfected groups showed
no difference in FOXP3 expression as a percentage of CD3
+CD4
+ T lymphocytes between the HIV and HIV/TB co-infected groups. Panel B:
Representative plots of baseline FOXP3 expression in CD3
+CD4
+ lymphocytes plotted against CD25 for a control and an HIV positive sample. Panel C:
Expression of FOXP3, CD25, CTLA-4 and GITR as a percentage of the CD3
+CD4
+ population. Panel D: Absolute numbers of total and FOXP3 expressing
CD4
+ T cells at baseline.
doi:10.1371/journal.pone.0011762.g001
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no use of biexponential axes. Not all samples were available for
analysis of all parameters, depending on CD4 count and numbers
of PBMCs available for culture.
Statistical Analysis
Statistical analyses were performed using SPSS version 15 and
GraphPad Prism version 4.0. Groups were compared by Mann
Whitney analysis and correlations performed using the Spearman
correlation coefficient. Significance was chosen at the 5% level.
Group medians are reported.
Results
CD4 counts of HIV-infected subjects
HIV infected subjects had CD4 counts ranging from 0 to 712
cells/ul (median CD4 count 216 cells/ul) with 48%of patients ,200
cells/ul group, 19% 200–350 cells/ul and 33% .350 cells/ul.
HIV infected subjects display higher percentages of CD4
+
T cells that express FOXP3 despite lower absolute
numbers
FOXP3 expression in CD4
+ T cells has been reported to confer
a regulatory phenotype and may be dysregulated in HIV infection.
To explore whether FOXP3 expression by CD4
+ T cells differs in
HIV infected individuals compared with controls, we isolated
PBMCs and performed intracellular cytokine staining after
overnight rest. In the control group, 3.72% of CD3
+CD4
+ T cells
were positive for FOXP3 (range from 1.3–7.5%), in keeping with
that described in the literature [10,56]. The HIV infected group
showed significantly elevated FOXP3 expression when expressed
as a percentage of total CD3
+CD4
+ cells (median of 8.11%, range
1.33–26.27%, P=0.002, Figure 1B,C). Absolute numbers of
FOXP3
+ CD4
+ T cells were lower in HIV positive patients than
controls (12.6 cells/ml versus 30.47 cells/ml, P=0.005, Figure 1C)
because of the lower CD4
+ T cell count. Similarly, there was lower
FOXP3 mRNA levels in HIV positive patients versus controls
(0.92 vs 1.35, P=0.03, data not shown).
FOXP3 expression in CD8
+T cells, while found at a much
lower proportion than CD4
+ T cells, has also been reported
[9,52,56,57,61,62,63,64] and may confer regulatory functions. It
is unknown if there is an alteration in CD8
+ Tc e l lF O X P 3
expression during HIV infection. We found FOXP3 expression
at low levels in the CD8
+ T cell population but no significant
difference between the control and HIV infected groups (0.20%
of CD3
+CD4
2 versus 0.39% respectively). FOXP3 expression on
the CD3
+CD4
2 population could be upregulated by antiCD3
stimulation (data not shown). There was however no significant
difference in stimulated FOXP3 expression of CD4
+ T cells or
CD8
+ (CD3
+CD4
2) T cells between the HIV and control
groups.
FOXP3 expression does not correlate with the activation
marker CD25
CD25 is often used as a marker of regulatory T cells but can also
act as an activation marker. CD25 expression in humans appears
as a continuum of expression rather than a discrete positive and
negative population, therefore to ensure reproducible gating,
CD25 was gated by selecting the total CD3
+ population and
plotting CD25 against CD4. FOXP3 expression on the CD4
2
population was used to set the positive gate. The resulting
percentage obtained was used to calculate the CD25 expression as
a percentage of the total CD3
+CD4
+ population (Figure 2).
CD25 expression gated in this manner did not differ significantly
between the HIV infected and control group. While FOXP3
+T
helper cells were visually CD25
high as expected, FOXP3% showed
nosignificantcorrelation withCD25 expression ineitherthecontrol
or HIV infected group. CD25 expression did not show a statistical
correlation with either viral load or CD4 count.
Examining other postulated markers of regulatory T cells,
CTLA4
+FOXP3
+ coexpression (as a percentage of CD3
+CD4
+
cells) was higher in the HIV group than the controls (0.78% versus
0.39%, P=0.009, Figure 2A). There was no significant difference
between the two groups in CD25
+, CTLA-4
+, GITR
+ or
GITR
+FOXP3
+ coexpression.
CD4
+ T cell FOXP3 expression is negatively correlated
with CD4
+ T cell count and positively correlated with viral
load
As FOXP3 expression may be affected by the degree of
immunodeficiency, we analysed the relationship between the
CD4
+T cell count and the percentage of CD4
+Tc e l l se x p r e s s i n g
FOXP3. There was a negative correlation demonstrable between
CD4 count and FOXP3 percentage in the HIV infected group
(rho=20.423 P=0.044, Figure 3A) but no significant correlation in
the control group (Figure 3B). Stratification based on CD4 count
revealed that it was only the samples with CD4 count ,200 cells/ml
that showed a marked elevation in FOXP3 percentage (median
10%), while there was no elevation in FOXP3 percentage insamples
with higherCD4 counts(5.09% insamples with CD4 countsof200–
350 cells/mla n d5 . 3 6 %i ns a m p l e s.350 cells/m) (Figure 3C).
As anticipated, there was a significant negative correlation
between viral load and CD4 count (rho=20.538 P=0.005, data
not shown). We further determined that FOXP3 percentage
correlated positively with viral load (rho=0.593 P=0.003,
Figure 3D).
High FOXP3 frequencies in HIV infected individuals are
not due to increased FOXP3
+ T cell lifespan nor increased
T cell proliferation
In order to assess the mechanism by which the FOXP3
frequency of total CD4 T cells is elevated in HIV infected patients,
we analysed FOXP3 expression in four-day cultures with and
without stimulation through the T cell receptor with anti-CD3.
Unexpectedly, unstimulated FOXP3 expression, expressed as a
percentage of CD3
+CD4
+cells,was significantlyloweronday4than
on day 1 in the HIV infected group (1.95% versus 9.75%, P,0.001)
whilst there was no significant drop in expression in the control
group(2.56% versus3.36%) (Figure 4A). Thissuggeststhat FOXP3
+
cells were not maintaining high levels due to a longer lifespan than
FOXP3
2 cells. After stimulation with anti-CD3, however, day 4
FOXP3 expression in the HIV infected group was comparable with
baseline and with day 4 control group levels(Figure 4A), suggesting
that mechanisms of FOXP3 upregulation after T cell receptor
triggering are intact in HIV infected individuals.
To assess whether FOXP3 upregulation was due to increased
CD4
+T cell proliferation or increased expression in proliferated
CD4
+ T cells, we assessed FOXP3 expression following anti-CD3
stimulation of CFSE stained cells. Total CD4
+ T cells proliferated
less in the HIV infected group than in the control group (13.09%
of CD3
+CD4
+ cells versus 60.08%, P=0.02, Fig 4B). FOXP3 was
upregulated in daughter cells (Figure 4C) but the percentage of
proliferating cells expressing FOXP3 did not differ in the HIV
infected and control groups (11.31% versus 11.78% Figure 4B).
Together, these findings suggest that high FOXP3 percentages
in HIV infected patients is not due to longer lifespan, increased cell
FOXP3 is Upregulated in HIV
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conclude that the increased FOXP3 frequencies in HIV infected
patients is likely due to upregulation of FOXP3 expression by
individual CD4
+ T cells, possibly following antigenic or other
stimulation.
Discussion
We used intracellular cytokine staining to analyse FOXP3
expression and other postulated markers of regulatory T cells
(CD25, CTLA4 and GITR) in HIV infected individuals. We
Figure 2. Representative plot illustrating CD25 gating strategy. Lymphocytes were gated according to forward and side scatter. CD3 positive
lymphocytes were selected. CD25 expression on the x-axis was plotted against CD4 on the y-axis. A gate was set according to CD25 expression on the
CD4
2 population. This gave a percentage of CD3
+CD4
+CD25
+ lymphocytes as a percentage of CD3
+ (figure in top-right quadrant). This percentage
was then used to calculate the percentage of CD3
+CD4
+CD25
+ lymphocytes as a percentage of the CD3
+CD4
+ population (CD4 population being top-
left and right quadrants added together).
doi:10.1371/journal.pone.0011762.g002
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percentage of CD4
+ T cells that expressed FOXP3 compared
with control individuals. The percentage of FOXP3 expressing
CD4
+ T cells correlated negatively with CD4 count and positively
with viral load. Due to their lower absolute CD4 count, the
absolute number of FOXP3 expressing cells, as well as FOXP3
mRNA expression, was found to be lower in HIV infected
individuals than in controls.
The finding of higher FOXP3 levels in patients with lower CD4
counts and higher viral loads is in keeping with the findings of
others [11,37,65]. The inverse relationship between CD4 count
and FOXP3 expression has not been consistently described and is
well illustrated in our sample group possibly due to the inclusion of
HIV infected patients with very low CD4 counts.This relationship
also explains why studies with patients with relatively high CD4
counts at enrolment may have failed to demonstrate elevations of
FOXP3 expression in peripheral blood. If the data is stratified into
patients according to CD4 count, it is only the patients with CD4
counts below 200 cells/ml who show a marked elevation in FOXP3
percentage of CD3
+CD4
+ T cells (median 10%) while there is no
significant difference in FOXP3 percentage between the 200–350
cells/mlo r.350 cells/ml group and the control group (Figure 3C).
We noted that FOXP3 positivity was not limited to the CD4
+ T
cell subset but was also observed on other CD4
2 T cells, albeit at
much lower levels. Interestingly, FOXP3 upregulation after anti-
CD3 stimulation, was noted on CD4
2 T cells as well as on CD4
+
T cells (data not shown). FOXP3 expression in CD8
+ T cells has
been described [9,52,56,57,61,62,63,64], as have other subsets of
FOXP3
2 CD8
+ cells with suppressor function [64,66,67,68,69]. In
contrast to the CD4
+FOXP3
+ subset, we saw no significant
difference in unstimulated or anti-CD3 stimulated percentages of
CD4
2FOXP3
+ cells between the control and HIV infected
groups.
HIV infected individuals are known to exhibit high levels of T
cell activation and debate reigns as to whether FOXP3 is
expressed by activated T cells that do not possess suppressive
functions [52,56,58]. In this study, stimulated FOXP3 expression
did correlate with in vitro proliferation of both CD4
+ and CD8
+ T
cells to anti-CD3 stimulation but there was no correlation
between expression of FOXP3 and the activation marker CD25.
The correlation of FOXP3 with cell proliferation may suggest
that FOXP3 acts as a marker of cell activation, however its
discordance with CD25 expression indicates otherwise. The lack
of statistical correlation between FOXP3 and CD25 expression,
gated in a reproducible manner, lends weight to the argument
that the elevated FOXP3 levels are not merely a marker of
activated cells in HIV infection, in keeping with findings [70]
describing dissociation between FOXP3 mRNA and CD25
expression in a SIV model. We took great care to gate CD25
using a reproducible gating strategy, namely using CD25
Figure 3. Correlation of FOXP3 with CD4 count and viral load. Panel A: CD4 count was negatively correlated with day 1 FOXP3 percentage in
the HIV infected group. Panel B: The control group showed no correlation between CD4 count and FOXP3 percentage. Panel C: FOXP3 percentage
stratified by CD4 count. Panel D: FOXP3 percentage was positively correlated with viral load.
doi:10.1371/journal.pone.0011762.g003
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2 T cells as the cutoff for CD25 positivity.
This proved a more reliable strategy than setting an arbitrary
threshold for CD25
+ and CD25
++. Future studies should,
however, include reference beads to allow more accurate CD25
determination. In previous studies, FOXP3 has also been shown
not to correlate with the activation markers CD69 [31] or CD38
[9] although there was a correlation with HLA-DR expression in
CD4
+ T cells in the latter study.
CTLA-4 and GITR did not coincide with FOXP3 expression ie
cells did not co-express FOXP3 with CTLA4 or GITR (Figure 1c).
This is in keeping with findings by Weiss et al. [8] of intracellular
CTLA-4 positivity in only 30% of Tregs (identified by
CD4
+CD25
hi expression) and Lim et al. [9] who found CTLA-4
or GITR expression in less than 10% of Tregs (CD4+CD25+
CD127
lo). A limitation of this study is that CD127 had not been
included, which may have given additional discriminatory power
of the Treg subset from activated cells. We therefore limited our
functional analysis to FOXP3 expression.
The finding of increased percentages of CD4
+ T cells expressing
FOXP3 in HIV infected individuals suggests that an imbalance of
Figure 4. FOXP3 expression after T cell receptor stimulation. Panel A: FOXP3 expression as a percentage of T lymphocytes at baseline
and after 4 days of cell culture, with and without T cell receptor stimulation with anti-CD3. Panel B: Proliferation of total CD4
+ Tc e l l sa n d
FOXP3
+ expression in proliferated CD4
+ T cells following T cell receptor stimulation with aCD3. Panel C: Representative plot of FOXP3
+
expression in proliferated T cells (left-hand plot) following anti-CD3 stimulation compared with an unstimulated sample(right-hand plot). The
small plots above show ancestry – lymphocytes were gated; followed by exclusion of events with high CFSE; followed by selection of
CD3
+CD4
+ T cells. Proliferation is demonstrated by halving of CFSE fluorescence in cells that have divided (large plots below). In the anti-CD3
stimulated sample, FOXP3 expression is noted in cells which have proliferated (top-left quadrant) as well as those that have not proliferated
(top-right quadrant).
doi:10.1371/journal.pone.0011762.g004
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to opportunistic infection. Higher FOXP3 expression could be the
result of one of four mechanisms: upregulated expression of
FOXP3 in individual CD4
+ T cells compared with HIV negative
individuals, increased proliferation of cells expressing FOXP3
+
cells, increased lifespan of FOXP3
+ cells or increased cell death of
FOXP3
2 CD4
+ T cells.
To analyse the mechanism of increased expression of FOXP3
amongst CD4
+ T cells from HIV infected individuals, we cultured
PBMCs from HIV infected and uninfected individuals in the
presence of a stimulating antibody against the T cell receptor (anti-
CD3). We found FOXP3 to be markedly upregulated by antigenic
stimulation with anti-CD3 stimulation.
We did not directly address the lifespan or susceptibility to cell
death of FOXP3 expressing cells in this study, however we noted
that during unstimulated culture conditions, the elevated FOXP3
levels in the HIV infected groups declined rapidly to control levels.
This is in keeping with a previous study suggesting that Tregs
(CD3
+CD25
hi) are highly susceptible to apoptosis in vitro due to
low levels of the antiapoptotic molecule Bcl-2 [54] and suggests
that they do not have a longer lifespan than FOXP3
2 cells.
In addition, FOXP3 expression in the HIV infected group could
be rescued by anti-CD3 to levels comparable with and the
stimulated control group. We explored whether this was due to
increased CD4
+ T cell proliferation or increased FOXP3
expression in cells which had proliferated. Using dual labelling
with CFSE and FOXP3 we found that total CD4
+ T cell
proliferation was lower in the HIV group than in the control
group, and the percentage of proliferated cells that expressed
FOXP3 was similar in both groups. Thus the mechanism by which
FOXP3 expression was upregulated in vitro in response to anti-
CD3 stimulation is not likely to be due to CD4
+ T cell
proliferation. Together, these findings suggest that elevated
FOXP3 percentages in HIV infected individuals is due to
upregulation of FOXP3 expression in individual CD4
+ T cells in
HIV, likely due to antigenic or other stimulation. The downstream
effect of FOXP3 upregulation was not directly addressed in this
study. Transient FOXP3 upregulation after T cell receptor
engagement may indicate that FOXP3 is an activation marker,
however does not exclude the possible acquisition of suppressive
potential after activation.
The debate over FOXP3 as activation marker versus marker of
suppressive activity may eventually prove both sides right. The
mechanisms of activation-induced cell death in healthy individ-
uals is poorly understood, but every activated cell must eventually
die or be suppressed, otherwise result in leukaemia. FOXP3 may
indeed be both an ‘‘activation marker’’ and a marker of cells that
have become unable to carryout effector functions.We have
shown that FOXP3 expression was transient and could be lost
and restimulated in HIV infected patients. Thus there did not
seem to be an increase in number of natural Tregs with lineage-
dependent FOXP3 expression in these patients, rather an
increase in FOXP3 expression induced peripherally. This may
be a result of cell activation, but the question remains as to why
the increased numbers of activated T cells in HIV infected
individuals fail to clear pathogens and are ineffectual in their
actions. While not directly addressed by this study, it is plausible
that continuous stimulation through the T cell receptor in HIV
infected individuals may induce chronic rather than transient
FOXP3 upregulation, resulting in dysfunctional effector T cells.
A difference in function between FOXP3 and other activation
markers may be an explanation for the discordance found in this
study between FOXP3 expression and expression of the
activation marker CD25.
It is recognised that CD4 count is not a perfect prognostic tool
for monitoring of HIV infected individuals, with some patients
appearing well even at low CD4 counts and some patients doing
poorly even with relatively high counts (in our study one patient
with a CD4 count of 2 appeared healthy). We suggest that FOXP3
expression in the CD4
+ T cell subset may prove a more accurate
prognostic tool to monitor disease progression and response to
antiretroviral therapy. Longitudinal studies should be conducted
to assess the use of FOXP3 frequency as a prognostic monitoring
tool.
The inclusion in our HIV patient cohort of some HIV infected
individuals with active Tuberculosis can be criticised, as there is
evidence suggesting changes in Treg number or function result
from Tuberculosis alone [71,72,73,74,75,76,77,78,79,80,81,82,83]
although these studies remain inconclusive. Roberts et al. [84]
found no difference in the levels of CD4
+CD25
+ Tregs in active
tuberculosis cases compared with latently infected controls in
unstimulated peripheral blood mononuclear cell cultures. Many of
these studies, as with studies of Tregs in HIV infection, have
assessed FOXP3 mRNA expression rather than FOXP3 protein
expression at the single cell level. Further, most quantitated Tregs
based on CD25 expression without the use of a reference marker
by which to set the CD25 gate. We conducted a subgroup analysis
which showed no significant difference in levels of FOXP3
expression in HIV infected individuals with and without
Tuberculosis (Figure 1A). Additionally, it can be hypothesized
that any defect in Treg number or function may be of a similar
nature in both HIV and Tuberculosis, given their propensity to
occur simultaneously. Thus the co-infected group may illustrate
more extreme changes not demonstrable in a small group of HIV
infected patients alone.
In conclusion, we have shown that HIV infected individuals had
significantly higher percentages of CD4
+ T cells positive for
FOXP3 than HIV uninfected individuals and that this is likely due
to upregulation of FOXP3 expression by CD4
+ T cells. FOXP3
expression as a percentage of CD4
+ T cells correlated positively
with viral load and negatively with CD4 count, with a marked
elevation in FOXP3 percentage in patients with CD4 counts
below 200 cells/ml. While correlation does not imply causation,
this data support the hypothesis that FOXP3 plays a functional
role in disease progression and may suppress responses to
pathogens. The basis of the increased FOXP3 expression appears
to be upregulation of FOXP3 expression by individual CD4
+ T
cells following T cell receptor stimulation. FOXP3 expression as a
percentage of the CD4
+ T cell population is a potential prognostic
marker of disease progression.
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